Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors

被引:10
|
作者
Menssouri, Naoual [1 ]
Poiraudeau, Loic [1 ]
Helissey, Carole [2 ]
Bigot, Ludovic [1 ]
Sabio, Jonathan [1 ]
Ibrahim, Tony [1 ]
Pobel, Cedric [1 ]
Nicotra, Claudio [3 ,5 ]
Ngo-Camus, Maud [3 ,5 ]
Lacroix, Ludovic [4 ,6 ]
Rouleau, Etienne [4 ,6 ]
Tselikas, Lambros [7 ]
Chauchereau, Anne [1 ]
Blanc-Durand, Felix [8 ]
Bernard-Tessier, Alice [8 ]
Patrikidou, Anna [8 ]
Naoun, Natacha [8 ]
Flippot, Ronan [8 ]
Colomba, Emeline [8 ]
Fuerea, Alina [8 ]
Albiges, Laurence [8 ]
Lavaud, Pernelle [8 ]
van de Wiel, Paul [9 ]
den Biezen, Eveline [9 ]
Wesseling-Rozendaal, Yvonne [9 ]
Ponce, Santiago [3 ,5 ]
Michiels, Stefan [10 ]
Massard, Christophe [3 ,5 ]
Gautheret, Daniel [11 ,12 ]
Barlesi, Fabrice [1 ]
Andre, Fabrice [1 ,11 ,12 ]
Besse, Benjamin [1 ,8 ,11 ]
Scoazec, Jean-Yves [1 ,4 ,6 ]
Friboulet, Luc [1 ]
Fizazi, Karim [1 ,8 ]
Loriot, Yohann [1 ,3 ,5 ,8 ,11 ,12 ,13 ]
机构
[1] Paris Saclay Univ, Inserm U981, Mol Predictors & New Targets Oncol, Gustave Roussy Canc Campus, Villejuif, France
[2] Hop Instruct Armees BEGIN, St Mande, France
[3] Drug Dev Dept DITEP, Gustave Roussy Canc Campus, Villejuif, France
[4] Expt & Translat Pathol Platform PETRA, Genom Platform Mol Biopathol Unit BMO, Gustave Roussy Canc Campus, Villejuif, France
[5] Biol Resource Ctr, AMMICA, INSERM US23, CNRS UMS3655, Villejuif, France
[6] Dept Med Biol & Pathol, Gustave Roussy Canc Campus, Villejuif, France
[7] Dept Intervent Radiol, Gustave Roussy Canc Campus, Villejuif, France
[8] Dept Med Oncol, Gustave Roussy Canc Campus, Villejuif, France
[9] InnoSIGN, High Tech Campus 11, Eindhoven, Netherlands
[10] Univ Paris Saclay, Oncostat U1018, Inserm, Labelled Ligue Canc, Villejuif, France
[11] Univ Paris Saclay, Dept Biostat & Epidemiol, Gustave Roussy, Villejuif, France
[12] PRISM Ctr Personalized Med, Gustave Roussy Canc Campus, Villejuif, France
[13] PRISM Ctr, DITEP, INSERM U981, Gustave Roussy Canc Campus,114 rue Edouard Vaillan, F-94805 Villejuif, France
关键词
MOLECULAR DETERMINANTS; INCREASED SURVIVAL; ENZALUTAMIDE; ABIRATERONE; EXPRESSION; SIGNATURES; EVOLUTION; MARKERS; MODELS;
D O I
10.1158/1078-0432.CCR-22-3736
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The androgen receptor axis inhibitors (ARPI; e.g., enzalutamide, abiraterone acetate) are administered in daily practice for men with metastatic castration-resistant prostate cancer (mCRPC). However, not all patients respond, and mechanisms of both primary and acquired resistance remain largely unknown.Experimental Design: In the prospective trial MATCH-R (NCT02517892), 59 patients with mCRPC underwent whole-exome sequencing (WES) and/or RNA sequencing (RNA-seq) of samples collected before starting ARPI. Also, 18 patients with mCRPC underwent biopsy at time of resistance. The objectives were to identify genomic alterations associated with resistance to ARPIs as well as to describe clonal evolution. Associations of genomic and transcriptomic alterations with primary resistance were determined using Wilcoxon and Fisher exact tests.Results: WES analysis indicated that no single-gene genomic alterations were strongly associated with primary resistance. RNA-seq analysis showed that androgen receptor (AR) gene alterations and expression levels were similar between responders and nonresponders. RNA-based pathway analysis found that patients with primary resistance had a higher Hedgehog pathway score, a lower AR pathway score and a lower NOTCH pathway score than patients with a response. Subclonal evolution and acquisition of new alterations in AR-related genes or neuroendocrine differentiation are associated with acquired resistance. ARPIs do not induce significant changes in the tumor transcriptome of most patients; however, programs associated with cell proliferation are enriched in resistant samples.Conclusions: Low AR activity, activation of stemness programs, and Hedgehog pathway were associated with primary ARPIs' resistance, whereas most acquired resistance was associated with subclonal evolution, AR-related events, and neuroendocrine differentiation. See related commentary by Slovin, p. 4323Conclusions: Low AR activity, activation of stemness programs, and Hedgehog pathway were associated with primary ARPIs' resistance, whereas most acquired resistance was associated with subclonal evolution, AR-related events, and neuroendocrine differentiation. See related commentary by Slovin, p. 4323
引用
收藏
页码:4504 / 4517
页数:14
相关论文
共 50 条
  • [1] Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
    Kostos, Louise
    Tran, Ben
    Azad, Arun A.
    DRUGS, 2024, 84 (09) : 1093 - 1109
  • [2] Targeting the androgen receptor in metastatic castration-resistant prostate cancer
    Aragon-Ching, Jeanny B.
    FUTURE ONCOLOGY, 2014, 10 (03) : 329 - 332
  • [3] Androgen Receptor Directed Therapies in Castration-Resistant Metastatic Prostate Cancer
    Won Kim
    Charles J Ryan
    Current Treatment Options in Oncology, 2012, 13 : 189 - 200
  • [4] Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
    Conteduca, Vincenza
    Jayaram, Anuradha
    Romero-Laorden, Nuria
    Wetterskog, Daniel
    Salvi, Samanta
    Gurioli, Giorgia
    Scarpi, Emanuela
    Castro, Elena
    Marin-Aguilera, Mercedes
    Lolli, Cristian
    Schepisi, Giuseppe
    Maugeri, Antonio
    Wingate, Anna
    Farolfi, Alberto
    Casadio, Valentina
    Medina, Ana
    Puente, Javier
    Mendez Vidal, Ma Jose
    Morales-Barrera, Rafael
    Villa-Guzman, Jose C.
    Hernando, Susana
    Rodriguez-Vida, Alejo
    Gonzalez-del-Alba, Aranzazu
    Mellado, Begona
    Gonzalez-Billalabeitia, Enrique
    Olmos, David
    Attard, Gerhardt
    De Giorgi, Ugo
    EUROPEAN UROLOGY, 2019, 75 (03) : 368 - 373
  • [5] Androgen Receptor Directed Therapies in Castration-Resistant Metastatic Prostate Cancer
    Kim, Won
    Ryan, Charles J.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2012, 13 (02) : 189 - 200
  • [6] Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
    George, Daniel J.
    Morgans, Alicia K.
    Constantinovici, Niculae
    Khan, Nasreen
    Khan, Javeed
    Chen, Guifang
    Hlebec, Vlasta
    Shore, Neal D.
    JAMA NETWORK OPEN, 2024, 7 (08)
  • [7] Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
    Obinata, Daisuke
    Lawrence, Mitchell G.
    Takayama, Kenichi
    Choo, Nicholas
    Risbridger, Gail P.
    Takahashi, Satoru
    Inoue, Satoshi
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [8] Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
    Yamada, Shigetomo
    Shiota, Masaki
    Blas, Leandro
    Matsumoto, Takashi
    Kashiwagi, Eiji
    Takeuchi, Ario
    Inokuchi, Junichi
    Shiga, Ken-Ichiro
    Yokomizo, Akira
    Eto, Masatoshi
    PROSTATE INTERNATIONAL, 2022, 10 (01) : 50 - 55
  • [9] Impact of Comorbidities and Drug Interactions in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors
    Zhong, Ying Yan
    Anton, Angelyn
    Xie, Owen
    Tan, Natalie
    O'Haire, Sophie
    Maleki, Sam
    Inderjeeth, Andrisha-Jade
    Parente, Phillip
    Spain, Lavinia
    Gibbs, Peter
    Tran, Ben
    JCO ONCOLOGY PRACTICE, 2024, 20 (09)
  • [10] Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer
    Schalken, Jack
    Fitzpatrick, John M.
    BJU INTERNATIONAL, 2016, 117 (02) : 215 - 225